Dimensional Fund Advisors LP raised its stake in shares of Tilray Inc (NASDAQ:TLRY - Free Report) by 54.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,172,935 shares of the company's stock after buying an additional 769,569 shares during the period. Dimensional Fund Advisors LP owned about 0.23% of Tilray worth $2,890,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Zacks Investment Management bought a new position in Tilray in the 4th quarter worth $41,000. NewEdge Advisors LLC boosted its holdings in Tilray by 92.1% in the 4th quarter. NewEdge Advisors LLC now owns 27,406 shares of the company's stock worth $36,000 after buying an additional 13,136 shares during the period. Canada Post Corp Registered Pension Plan bought a new position in Tilray in the 4th quarter worth $253,000. Quinn Opportunity Partners LLC boosted its holdings in Tilray by 108.0% in the 4th quarter. Quinn Opportunity Partners LLC now owns 1,618,080 shares of the company's stock worth $2,152,000 after buying an additional 840,000 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Tilray in the 4th quarter worth $255,000. 9.35% of the stock is currently owned by hedge funds and other institutional investors.
Tilray Price Performance
Shares of Tilray stock traded up $0.06 during trading on Friday, reaching $0.50. 37,838,118 shares of the stock traded hands, compared to its average volume of 28,195,479. The company has a market capitalization of $498.22 million, a price-to-earnings ratio of -1.65 and a beta of 1.95. The business has a fifty day simple moving average of $0.53 and a two-hundred day simple moving average of $0.96. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. Tilray Inc has a 52-week low of $0.41 and a 52-week high of $2.15.
Tilray (NASDAQ:TLRY - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The business had revenue of $185.78 million during the quarter, compared to the consensus estimate of $213.38 million. Sell-side analysts expect that Tilray Inc will post -0.2 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on TLRY. Piper Sandler cut their price objective on Tilray from $2.00 to $1.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Roth Capital restated a "neutral" rating on shares of Tilray in a research report on Monday, April 14th.
Get Our Latest Stock Report on TLRY
Tilray Company Profile
(
Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Stories

Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.